StockData
Legend Biotech Corp logo

Legend Biotech Corp (LEGN) stock

LEGNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 10, 2026Score 3/30
$15.25−0.85 (-5.28%)

Close on Nov 20, 2026Market cap $2.82BP/E –Yield –

Legend Biotech net income

Net income is the profit left for shareholders after every expense, interest and tax.

Legend Biotech's net income for the twelve months ending Mar 31, 2025 was -$218.15M. For fiscal 2024 it was -$177.03M. The highest annual figure on record is -$2.78M in fiscal 2018.

Annual net income

PeriodPeriod endValueChange
FY2024Dec 31, 2024-$177.03M–
FY2023Dec 31, 2023-$518.25M–
FY2022Dec 31, 2022-$446.35M–
FY2021Dec 31, 2021-$403.58M–
FY2020Dec 31, 2020-$266.37M–
FY2019Dec 31, 2019-$101.59M–
FY2018Dec 31, 2018-$2.78M–

Quarterly net income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q1 FY2025Mar 31, 2025-$100.92M–
Q4 FY2024Dec 31, 2024$26.28M–
Q3 FY2024Sep 30, 2024-$125.32M–
Q2 FY2024Jun 30, 2024-$18.20M–
Q1 FY2024Mar 31, 2024-$59.79M–
Q4 FY2023Dec 31, 2023-$144.82M–
Q3 FY2023Sep 30, 2023-$62.21M–
Q2 FY2023Jun 30, 2023-$199.13M–
Q1 FY2023Mar 31, 2023-$112.10M–
Q4 FY2022Dec 31, 2022-$135.88M–
Q3 FY2022Sep 30, 2022-$84.96M–

More Legend Biotech figures

See a number that looks wrong?